A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)

This study assessed the net health benefits of treatment with nivolumab versus everolimus among patients with advanced renal cell carcinoma by assessing the quality (ie, patient preferences) and quantity of survival (ie, time spent with significant toxicities, in progression, or before progression a...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Ruchitbhai, Botteman, Marc, Solem, Caitlyn T., Luo, Linlin, Doan, Justin, Cella, David, Motzer, Robert J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262523/
https://www.ncbi.nlm.nih.gov/pubmed/31272883
http://dx.doi.org/10.1016/j.clgc.2019.05.010

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262523/
https://www.ncbi.nlm.nih.gov/pubmed/31272883
http://dx.doi.org/10.1016/j.clgc.2019.05.010

Ejemplares similares